China Pharma ( NYSE: CPHI ) Monday said that it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. It is a medical treatment device for dry eye disease under patent protection. China Pharma ( CPHI ), through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registration and application process of the product.
In China, the incidence of dry eye disease is about 21%-30%, second only to myopia, the company said. Source: Press Release More on China Pharma Financial information for China Pharma.
